KGOG Information


Former Presidents

2002The Korean Gynecologic Oncology Group was established in October

When the new executive branch of the Korean Society of Gynecologic Oncology & Colposcopy was launched in fall of 2002, with the launch of the new executive branch of the Korean Society of Gynecologic Oncology & Colposcopy, the Korean Gynecologic Oncology Group was established within the society under the leadership of President Seong-eun Namgoong and Vice President Sun-beom Kang.

It is to actively accept advanced multicenter trial models represented by GOG in the US, EORTC in Europe, and JGOG in neighboring Japan. Furthermore, it is to lay the groundwork for joint research with these institutions.

The first year can be summarized as the birth and preparation period of the KGOG. From the following year, 2003, activities were actively carried out under the leadership of Sun-beom Kang, the First President of the KGOG. The main KGOG is composed of a president, a research committee, and operating committees for each topic. It also has the Cervical Cancer, Ovarian Cancer, and Endometrial Cancer Subcommittee and the Pathology, Radiotherapy, Medical Oncology, and Translational Research Subcommittee as advisory bodies.


  • 2003.01.25

    Opinions were exchanged on the formation of the KGOG preparatory committee, the drafting of the bylaws of the KGOG, and the clinical trial protocol until the third detailed operating committee meeting, starting with the first detailed operating committee meeting until the 3rd detailed operating committee meeting. Based on this, the first research committee was held.

  • 2003.04.17

    The 1st research committee meeting established the roles and goals of the KGOG: It aims to supervise a systematic and organized large-scale multicenter clinical study in research on the treatment of gynecological cancer and lead the standardization and development of domestic gynecological cancer specialist education”. It also discussed the roles of the Protocol Committee.

  • 2003.10.22

    The 6th detailed operating committee meeting decided the protocol for a phase 2 clinical trial on the efficacy and safety of paclitaxel/carboplatin concurrent chemoradiation in cervical cancer patients with a high risk of recurrence after extensive hysterectomy and the protocol for a multicenter, single-group, open-label phase 2 clinical trial on the efficacy and safety of gemcitabine triplet (Paclitaxel + Carboplatin + Gemcitabine) as consolidation chemotherapy in patients with advanced ovarian cancer (stage III-IV).

  • 2004.02.19

    The 2nd research committee meeting was held, and it discussed details for the confirmed protocol, fund operation, research nurses and office preparation, CRF form preparation, and model document preparation for each hospital's IRB approval.

  • 2004.03.08

    The 9th detailed operating committee meeting discussed the details of the contents discussed in the 2nd research committee.

  • 2004.04.06

    The 10th detailed operating committee meeting decided to investigate the principles of GOG and JGOG to prepare principles for developing protocol serial numbers.

  • 2004.04.27

    The 11th detailed operating committee meeting determined the principles for protocol serial numbers. It also introduced the new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer), GOG standards for evaluation for membership, and the EORTC Gynecological Cancer Group Application Form. From the 12th detailed operating committee meeting to the 14th detailed operating committee meeting, the KGOG-1001 protocol and KGOG-3001 protocol were finally supplemented and finalized.

  • 2004.07.26

    The 14th detailed operating committee meeting introduced web programming for collecting case records and DB carboplatin dose calculator (excel file). Moreover, Professor Jae-won Kim presented the observation of the GCIG semi-annual meeting and Professor Young-tae Kim also presented the observation of the GOG at this meeting. It conducted a literature review on the adjuvant treatment of the endometrial cancer high-risk group and discussed the direction of protocol progress.